Zilovertamab Vedotin

• A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign… Recruiting
  2022-501374-19-00 Phase II 9 countries Merck Sharp & Dohme LLC
• A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1… Recruiting
  2023-506384-34-00 Phase I (FiH) 4 countries Merck Sharp & Dohme LLC
• A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting
  2024-515526-89-00 Phase II 5 countries Merck Sharp & Dohme LLC
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 Phase III 11 countries Merck Sharp & Dohme LLC
• LIGHTBEAM-U01-Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Pa… Recruiting
  2023-507178-41-00 Phase I/II 12 countries Merck Sharp & Dohme LLC
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-C… Recruiting
  2022-502646-27-00 Phase II/III 5 countries Merck Sharp & Dohme LLC
• A Study of an experimental drug, MK-2140 in combination with standard of care chemotherapy in participants with Diffuse Large B-Cell Lymphom… Ended
  2022-501380-40-00 Phase II 3 countries Merck Sharp & Dohme LLC
• A Research Study, where the participant and healthcare providers are aware of the treatment being given, to evaluate safety and effectivenes… Ended
  2022-501243-33-00 Phase II 9 countries Merck Sharp & Dohme LLC

Showing 1–8 of 8 trials